Rituximab alone provides extended remission in follicular lymphoma

By Ross Bonander, September 23, 2010
rituximab.jpg

Results of the Swiss Group for Clinical Cancer Research (SAKK) Trial 35/98 have been published, and the results indicate potential extra benefits to long-term single-agent rituximab in certain patients with follicular lymphoma …

Read more of this story at CancerTreatment.net.

disclaimer text

You May Also Want To Read

JCO.jpg
High BMI Associated With Improved Survival in DLBCL
According to the findings of a retrospective analysis of over 2,500 US military veterans diagnosed with diffuse large B-cell lymphoma (DLBCL) between...
Ibritumomab_tiuxetan_structure.jpg
Zevalin Added to SCT Boosts Survival in Refractory Follicular Lymphoma
Spectrum Pharmaceuticals is announcing that positive long-term clinical data for the Zevalin® therapeutic regimen has been published in the journa...
ASCO 2012.jpg
Treanda + Rituxan Wins Praise Over R-CHOP
Fewer side effects, a lower toxicity profile, and a better treatment outcome—all ideal hopes for cancer treatments, and according to a study presented...


Subscribe to Our Newsletter to Receive Lymphoma News and Support

Email

Learn More

tcell
Promising New Trial for Relapsed B-Cell Lymphoma
B cell lymphoma is notoriously unresponsive when it returns after treatment. Scientists at City of...
ASH-logo.jpg
Type 2 diabetes A Risk Factor For Blood Cancers
A meta-analysis led by researchers at the Miriam Hospital and published in the journal Blood found t...
Biovest.jpg
BiovaxID Demonstrates High Overall Survival in Mantle Cell Lymphoma
Biovest has announced that the National Cancer Institute (NCI) has presented outcomes at this past w...
Burkitt_lymphoma.jpg
Burkitt Lymphoma Much Different Than Other B-Cell Lymphomas
Scientists at the National Cancer Institute (NCI) have uncovered the first evidence that Burkitt lym...
zevalin.jpg
Phase III Trial Initiated for Radioimmunotherapy Zevalin Against DLBCL
Spectrum Pharmaceuticals, makers of the radioimmunotherapy treatment Zevalin, have announced the ini...
PANOBINOSTAT_IMG.gif
Panobinostat Could Benefit Some With Refractory Hodgkin's
According to research published recently in the Journal of Clinical Oncology, the investigational dr...

Poll

Why Did You Visit This Site?:

LymphomaInfo Social

rss feed for lymphomainfo